CD274 and gastric cancer: The ATTRACTION-2 study, a phase III, randomized clinical trial, compared the effectiveness of a monoclonal antibody nivolumab against PD-L1, in individuals with advanced gastric cancer and revealed that nivolumab greatly increased overall survival and reduced the risk of mortality (10).